First 10 operating room procedures with SmartFrame OR successfully completed. Company expects positive impact to revenue in 2024 due to OR expansion.
SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the Company), a global device, cell, and gene therapy-enabling company offering precise navigation...
ClearPoint Neuro's partner's completed BLA Submission for Upstaza„ would be first disease-modifying treatment for AADC Deficiency in the US.
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results
Journal of Neurosurgery Publication Shows Advantage of ClearPoint Therapy System
ClearPoint to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
ClearPoint Announces Pricing of Offering of 2,307,694 Shares of Common Stock
SOLANA BEACH, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the Company), a global device, cell, and gene therapy-enabling company offering precise navigation to...
ClearPoint Neuro announces FDA Clearance and first-in-human cases using 2.2 Software with integrated Maestro Brain Modeling, and publication in NeuroImage
First successful procedure with ClearPoint Prism Neuro Laser Therapy System and Neuro Navigation System by Kaleida Health in Buffalo.